Drug Name:
Sulfadoxine+Pyrimetdhamine tablet
Ingredients:
Each tablet contains Sulfadoxine 500mg,Pyrimethamine 25mg 
Indications:
Sulfadoxine and Pyrimethamine tablets are indicated for Intermittent Preventive Treatment(IPT) of malaria in pregnancy.
(1) IPT is recommended in areas of high malaria transmission.
(2) IPT is administered with each scheduled visit after quickening to ensure at least 2 doses are given.
(3) Women known to be HIV-Infected or with unknown HIV status living in areas of high HIV prevelance(>10% among pregnant women) should receive at least 3 doses of IPT.
(4) IPT should be given at an interval of at least 4 weeks (1 month).
(5) Pregnant women who are HIV positive and are also taking antiretroviral therapy for PMTCT should receive IPT.
Sulfadoxine and Pyrimethamine tablet is also recommended as an adjunctive therapy to be used on the last day of oral quinine sulphatetherapy in the treatment of severe malarial infections for optimal clinical response.
Adverse Effects:
Agranulocytosis, aplastic anemia, megaloblastic anemia, thrombocytopenia, leukopenia, hemolytic anemia, purpura, hypoprothrombinemia, methemoglobinemia, and eosinophilia.
Erythema multiforme, Stevens-Johnson syndrome, generalized skin eruptions, toxic epidermal necrolysis, urticaria, serum sickness, pruritus, exfoliative dermatitis, anaphylactoid reactions, periorbital edema, conjunctival and scleral injection, photosensitization, arthralgia, allergic myocarditis, slight hair loss, Lyell's syndrome,
Glossitis, stomatitis, nausea, emesis, abdominal pains, hepatitis, hepatocellular necrosis, diarrhea, pancreatitis, feeling of fullness, and transient rise of liver enzymes.
Headache, peripheral neuritis, mental depression, convulsions, ataxia, hallucinations, tinnitus, vertigo, insomnia, apathy, fatigue, muscle weakness, nervousness, and polyneuritis.
Pulmonary infiltrates resembling eosinophilic or allergic alveolitis.
Renal failure, interstitial nephritis, BUN and serum creatinine elevation, toxic nephrosis with oliguria and anuria, and crystalluria.
Drug fever, chills, periarteritis nodosa and LE phenomenon have occurred.
Warning:
Fatalities associated with the administration of sulfonamides, although rare, have occurred due to severe reactions, including fulminant hepatic necrosis, agranulocytosis, aplastic anemia and other blood dyscrasias. Fansidar (sulfadoxine and pyrimethamine) prophylactic regimen has been reported to cause leukopenia during a treatment of 2 months or longer. This leukopenia is generally mild and reversible.
Packing specification:
3's/box
Usage and dosage:
Oral, as directed by your doctor
for Export use only